Consensus Medivir AB

Equities

MVIR B

SE0020181014

Delayed Nasdaq Stockholm Other stock markets 09:06:56 2024-05-14 am EDT			5-day change	1st Jan Change
2.91 ^SEK	-1.36%		-3.00%	+2.11%

May. 07	Medivir Aktiebolag Approves Board Appointments	CI
Apr. 30	Transcript : Medivir AB, Q1 2024 Earnings Call, Apr 30, 2024

Evolution of the average Target Price on Medivir AB

Price target over the last 5 years

History of analyst recommendation changes

c0a8c3b576c20a0836cebeaed7aefa0.nktffLeVs5a03c2J1sB35pCQJ6gSnSXm6e39BdQKx6U.zwFyFeLEyqPAk4b7oJgk0t_hCppTq1Xf2drOQa5GktDvAC01mqTE08Ct_Q~28905f25807446760cdacb3103e7e4f6

Analyst Recommendations on Medivir AB

Medivir Says Phase 2a Study of Fostrox With Lenvima Has 17% Overall Response Rate, 72% Disease Control Rate

23-10-05

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.95 SEK

Average target price

20.62 SEK

Spread / Average Target

+598.87%

High Price Target

54 SEK

Spread / Highest target

+1,730.51%

Low Price Target

8 SEK

Spread / Lowest Target

+171.19%

Consensus detail

Consensus revision (last 18 months)

Ratings for Medivir AB

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar